Behcet Syndrome Clinical Trial
Official title:
ModulAtion of Gut Microbiota Through Nutritional Interventions in Behcet's Syndrome pAtients: the MAMBA Study
NCT number | NCT03962335 |
Other study ID # | MAMBA |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 6, 2019 |
Est. completion date | May 31, 2023 |
Verified date | February 2024 |
Source | Azienda Ospedaliero-Universitaria Careggi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Behçet's syndrome (BS) is an idiopathic, chronic, multi-systemic inflammatory disorder characterized by ocular disease, skin lesions, vascular, neurological and gastrointestinal involvement. A recent study showed a peculiar dysbiosis of gut microbiota (GM) in BS patients, with specific changes in the profiles of short-chain fatty acids, especially butyrate. Over the last few years, a growing interest on the role of GM in metabolic disturbances has been manifested. Diet is one of the major factors driving the GM composition and functionality. In this context, the influence of diets generally recognized healthy on GM has been explored, but consistent data on autoimmune and inflammatory diseases are not available. The aim of this intervention study is to investigate whether a lacto-ovo-vegetarian diet enriched in substrates with potential for butyrate production or a Mediterranean diet supplemented with oral butyrate could be beneficial for GM and metabolic risk profile in BS.
Status | Completed |
Enrollment | 90 |
Est. completion date | May 31, 2023 |
Est. primary completion date | May 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Behcet syndrome - Age 18-65 years - Willing to give informed consent - Willing to participate in a study where one of the proposed dietary profile is a vegetarian pattern Exclusion Criteria: - Pregnancy or lactation - Concomitant presence of serious illness or unstable condition (autoimmune diseases; chronic viral infections; malignancies, recent myocardial infarction, chronic liver disease, inflammatory bowel diseases) - Current or recent (past 6 months) participation in weight loss treatment program or use of weight loss medication - Adoption of a vegetarian diet for the past 3 months |
Country | Name | City | State |
---|---|---|---|
Italy | Unit of Clinical Nutrition, University Hospital of Careggi | Florence |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliero-Universitaria Careggi |
Italy,
Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, Peano C, Turroni S, Rampelli S, Pozzilli P, Pianesi M, Fallucca F, Brigidi P. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. Br J Nutr. 2016 Jul;116(1):80-93. doi: 10.1017/S0007114516001045. Epub 2016 May 6. — View Citation
Candela M, Maccaferri S, Turroni S, Carnevali P, Brigidi P. Functional intestinal microbiome, new frontiers in prebiotic design. Int J Food Microbiol. 2010 Jun 15;140(2-3):93-101. doi: 10.1016/j.ijfoodmicro.2010.04.017. Epub 2010 Apr 24. — View Citation
Candela M, Rampelli S, Turroni S, Severgnini M, Consolandi C, De Bellis G, Masetti R, Ricci G, Pession A, Brigidi P. Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 2012 Jun 6;12:95. doi: 10.1186/1471-2180-12-95. — View Citation
Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, Grassi A, Rampelli S, Silvestri E, Centanni M, Cianchi F, Gotti R, Emmi L, Brigidi P, Bizzaro N, De Bellis G, Prisco D, Candela M, D'Elios MM. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015 Apr;14(4):269-76. doi: 10.1016/j.autrev.2014.11.009. Epub 2014 Nov 27. — View Citation
Haro C, Montes-Borrego M, Rangel-Zuniga OA, Alcala-Diaz JF, Gomez-Delgado F, Perez-Martinez P, Delgado-Lista J, Quintana-Navarro GM, Tinahones FJ, Landa BB, Lopez-Miranda J, Camargo A, Perez-Jimenez F. Two Healthy Diets Modulate Gut Microbial Community Improving Insulin Sensitivity in a Human Obese Population. J Clin Endocrinol Metab. 2016 Jan;101(1):233-42. doi: 10.1210/jc.2015-3351. Epub 2015 Oct 27. — View Citation
International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. doi: 10.1111/jdv.12107. Epub 2013 Feb 26. — View Citation
Kabeerdoss J, Devi RS, Mary RR, Ramakrishna BS. Faecal microbiota composition in vegetarians: comparison with omnivores in a cohort of young women in southern India. Br J Nutr. 2012 Sep 28;108(6):953-7. doi: 10.1017/S0007114511006362. Epub 2011 Dec 20. — View Citation
Kosiewicz MM, Dryden GW, Chhabra A, Alard P. Relationship between gut microbiota and development of T cell associated disease. FEBS Lett. 2014 Nov 17;588(22):4195-206. doi: 10.1016/j.febslet.2014.03.019. Epub 2014 Mar 26. — View Citation
Munoz-Gonzalez I, Jimenez-Giron A, Martin-Alvarez PJ, Bartolome B, Moreno-Arribas MV. Profiling of microbial-derived phenolic metabolites in human feces after moderate red wine intake. J Agric Food Chem. 2013 Oct 2;61(39):9470-9. doi: 10.1021/jf4025135. Epub 2013 Sep 19. — View Citation
Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009 Jan;136(1):65-80. doi: 10.1053/j.gastro.2008.10.080. Epub 2008 Nov 19. — View Citation
Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet's disease: a review. World J Gastroenterol. 2015 Apr 7;21(13):3801-12. doi: 10.3748/wjg.v21.i13.3801. — View Citation
Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014 Nov 4;20(5):779-786. doi: 10.1016/j.cmet.2014.07.003. Epub 2014 Aug 21. — View Citation
Wong JM. Gut microbiota and cardiometabolic outcomes: influence of dietary patterns and their associated components. Am J Clin Nutr. 2014 Jul;100 Suppl 1:369S-77S. doi: 10.3945/ajcn.113.071639. Epub 2014 Jun 4. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease severity of Behcet syndrome assessed by Behc¸et Disease Current Activity Form | The disease activity will be assessed by the use of the validated Behc¸et Disease Current Activity Form (BCDAF), at the baseline and after the dietary intervention. The BCDAF will assess the presence of oral and genital ulceration, skin, joint and gastrointestinal involvement, presence of fatigue and headache with a 5-point scale according to the duration of symptoms, with 0 meaning no symptoms and 4 meaning symptoms for 4 weeks. The presence of eyes, large vessels or central nervous system (CNS) involvement are document with "yes/no" answers. In addition, patients will be asked to rate on a 7-point scale how active they felt. Similarly, the clinicians will complete a 7-rating scale to assess their opinion of overall activity of the disease, with lower scores representing better outcomes. | 1 year | |
Primary | Behcet disease's improvement of symptoms assessed by the Global Assessment of Improvement Scale (GAI) modified form | The Global Assessment of Improvement Scale (GAI) modified form will assess Behcet disease's improvement of symptoms using a 7-point scale, with higher scores meaning an improvement of the symptoms. The severity of abdominal pain, severity of abdominal distention, satisfaction with bowel habits, severity of headache, severity of exhaustion, severity of nausea, attention disorder, muscle/joint pain, and quality of life will be investigated in response to the following question: "Compared to the way you felt before you entered the study, have your symptoms over the past 7 days been: 1) "Substantially Worse", 2) "Moderately Worse, 3) "Slightly Worse", 4) "No Change", 5) "Slightly Improved", 6) "Moderately Improved" or 7) "Substantially Improved". | 1 year | |
Primary | Behcet disease's severity of gastrointestinal symptoms assessed by the Symptom Severity Scale (SSS) modified form | The Symptom Severity Scale (SSS) modified form is a multidimensional rating scale assessing overall symptoms' severity on a Visual Analogue Scale (VAS). An overall score will be calculated from six items: pain severity, pain frequency, abdominal bloating, bowel habit dissatisfaction, abdominal heaviness, and life interference. The modified SSS ranges from 0 to 600, with higher scores meaning more severe symptoms. | 1 year | |
Secondary | Gut microbiota assessed by Illumina MiSeq platform | Changes of gut microbiota profiles from baseline. The V3 and V4 hypervariable regions of the 16S rRNA gene will be sequenced on Illumina MiSeq platform, following the Illumina protocol for 16S Metagenomic Sequencing Library Preparation | 1 year | |
Secondary | Fecal SCFA assessed by Gas Chromatography - Mass Spectrometry system | Fecal SCFA's change from baseline, especially butyrate, will be assessed by Gas Chromatography - Mass Spectrometry system | 1 year | |
Secondary | Inflammatory profile assessed by cytofluorimetric approach | Inflammatory cytokines' change from baseline, will be assessed with the Bio-Plex cytokine assay, according to the manufacturer's instructions. In particular, Interleukin (IL)-1ra (pg/mL), IL-4 (pg/mL), IL-6 (pg/mL), IL-8 (pg/mL), IL-10 (pg/mL), IL-12 (pg/mL), IL-17 (pg/mL), monocyte chemoattractant protein (MCP)-1 (pg/mL), macrophage inflammatory protein (MIP)-1beta (pg/mL), vascular endothelial growth factor (VEGF) (pg/mL), tumor necrosis factor (TNF)-alpha (pg/mL), interferon (IFN)-gamma (pg/mL), interferon-gamma-induced protein (IP)-10 (pg/mL), will be measured. | 1 year | |
Secondary | Lipid peroxidation assessed by flow cytometry | Lipid peroxidation markers' change from baseline will be estimated using the Thiobarbituric Acid Reactive Substances (TBARS, pg/mL) assay kit through the flow cytometry. | 1 year | |
Secondary | Plasma total antioxidant capacity assessed by the oxygen radical absorbance capacity | Plasma total antioxidant capacity's (TAC, µmol/mL) change from baseline, will be measured using the oxygen radical absorbance capacity. | 1 year | |
Secondary | Reactive oxygen species (ROS) assessed by flow cytometry | Leukocyte (lymphocyte, monocyte, and granulocyte) reactive oxygen species' (ROS, RFU) change from baseline will be assessed through flow cytometry | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274648 -
Dietary Interventions and Butyrate Production in Behçet's Patients
|
N/A | |
Terminated |
NCT01693653 -
Tocilizumab for the Treatment of Behcet's Syndrome
|
Phase 2 | |
Completed |
NCT04961463 -
Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model
|
N/A | |
Completed |
NCT05142995 -
Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
|
||
Recruiting |
NCT00931957 -
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
|
N/A | |
Completed |
NCT03514056 -
Frequency of Fibromyalgia in Behcet Disease
|
||
Not yet recruiting |
NCT03771768 -
Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease
|
N/A | |
Terminated |
NCT03554161 -
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Recruiting |
NCT04738864 -
Neuro-ultrasound Assessment in Behcet's Disease
|
N/A | |
Completed |
NCT03264391 -
Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
|
||
Completed |
NCT04386824 -
Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
|
||
Completed |
NCT01532570 -
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
|
Phase 3 | |
Not yet recruiting |
NCT04186559 -
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
|
Phase 2 | |
Terminated |
NCT04218565 -
Golimumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Not yet recruiting |
NCT03747354 -
Assessment of Disease Activity in Behcet by Complete Blood Count
|
N/A | |
Recruiting |
NCT05200715 -
AutoInflammatory Disease Alliance Registry (AIDA)
|
||
Completed |
NCT05098678 -
Zinc Supplementation and Behçet's Syndrome
|
N/A | |
Completed |
NCT00866359 -
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
|
Phase 2 | |
Completed |
NCT00483184 -
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
|
Phase 2 | |
Completed |
NCT05032248 -
Uses of Tacrolimus in Behcet Disease
|
N/A |